Taiani J T, Buie H R, Campbell G M, Manske S L, Krawetz R J, Rancourt D E, Boyd S K, Matyas J R
McCaig Institute for Bone and Joint Health, Faculty of Medicine, University of Calgary, Calgary, AB, T2N 4N1, Canada; Biomedical Engineering Program, University of Calgary, Calgary, AB, T2N 1N4, Canada.
McCaig Institute for Bone and Joint Health, Faculty of Medicine, University of Calgary, Calgary, AB, T2N 4N1, Canada; Schulich School of Engineering, University of Calgary, Calgary, AB, T2N 1N4, Canada.
Bone. 2014 Jul;64:263-72. doi: 10.1016/j.bone.2014.04.019. Epub 2014 Apr 26.
In the current study, we used an estrogen-deficient mouse model of osteoporosis to test the efficacy of a cell-generated bone tissue construct for bone augmentation of an impaired healing fracture. A reduction in new bone formation at the defect site was observed in ovariectomized fractures compared to the control group using repeated measures in vivo micro-computed tomography (μCT) imaging over 4 weeks. A significant increase in the bone mineral density (BMD), trabecular bone volume ratio, and trabecular number, thickness and connectivity were associated with fracture repair in the control group, whereas the fractured bones of the ovariectomized mice exhibited a loss in all of these parameters (p<0.001). In a separate group, ovariectomized fractures were treated with murine embryonic stem (ES) cell-derived osteoblasts loaded in a three-dimensional collagen I gel and recovery of the bone at the defect site was observed. A significant increase in the trabecular bone volume ratio (p<0.001) and trabecular number (p<0.01) was observed by 4 weeks in the fractures treated with cell-loaded collagen matrix compared to those treated with collagen I alone. The stem cell-derived osteoblasts were identified at the fracture site at 4 weeks post-implantation through in situ hybridization histochemistry. Although this cell tracking method was effective, the formation of an ectopic cellular nodule adjacent to the knee joints of two mice suggested that alternative in vivo cell tracking methods should be employed in order to definitively assess migration of the implanted cells. To our knowledge, this study is the first of its kind to examine the efficacy of stem cell therapy for fracture repair in an osteoporosis-related fracture model in vivo. The findings presented provide novel insight into the use of stem cell therapies for bone injuries.
在当前研究中,我们使用骨质疏松雌激素缺乏小鼠模型来测试细胞生成的骨组织构建体对愈合受损骨折进行骨增强的疗效。与对照组相比,通过在4周内重复进行体内微型计算机断层扫描(μCT)成像,观察到去卵巢骨折的缺损部位新骨形成减少。对照组骨折修复与骨矿物质密度(BMD)、小梁骨体积比、小梁数量、厚度和连通性显著增加相关,而去卵巢小鼠的骨折骨在所有这些参数上均出现下降(p<0.001)。在另一组中,将装载于三维I型胶原凝胶中的小鼠胚胎干(ES)细胞来源的成骨细胞用于治疗去卵巢骨折,并观察缺损部位骨的恢复情况。与单独使用I型胶原治疗的骨折相比,在装载细胞的胶原基质治疗的骨折中,4周时观察到小梁骨体积比显著增加(p<0.001)和小梁数量显著增加(p<0.01)。通过原位杂交组织化学在植入后4周在骨折部位鉴定出干细胞来源的成骨细胞。尽管这种细胞追踪方法有效,但两只小鼠膝关节附近形成异位细胞结节表明,应采用其他体内细胞追踪方法以明确评估植入细胞的迁移。据我们所知,本研究是首次在体内骨质疏松相关骨折模型中研究干细胞疗法对骨折修复疗效的同类研究。所呈现的研究结果为干细胞疗法用于骨损伤提供了新的见解。